Relationship of plasma neuropeptide y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction

Heart

Volumn 99, Issue 16, 2013, Pages 1198-1203

  Cuculi, Florim ^a   Herring, Neil ^b   De Caterina, Alberto R ^a   Banning, Adrian P ^a   Prendergast, Bernard D ^a   Forfar, John C ^a   Choudhury, Robin P ^b   Channon, Keith M ^b   Kharbanda, Rajesh K ^a,b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; NEUROPEPTIDE Y; PRASUGREL;

ACUTE HEART INFARCTION; ADULT; ANALYZER; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; BLOOD SAMPLING; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORONARY FLOW RESERVE; CORONARY PHYSIOLOGY INDEX; CORONARY STENT; DIABETES MELLITUS; DRUG ELUTING STENT; ELECTROCARDIOGRAPHY; ELISA KIT; FEMALE; HEART MUSCLE REPERFUSION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; MICROCIRCULATORY RESISTANCE; NEUROPEPTIDE Y BLOOD LEVEL; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRESSURE WIRE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REFERENCE VALUE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TACHYCARDIA; THROMBUS; UNIVERSITY HOSPITAL; VASCULAR RESISTANCE;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; ELECTROCARDIOGRAPHY; ENGLAND; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; MYOCARDIAL INFARCTION; NEUROPEPTIDE Y; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84880634708     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-303443     Document Type: Article

References (30)

1. Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol 2009;54:281-92.
2. Cuculi F, De Caterina AR, Kharbanda RK, et al. Optimal reperfusion in ST-elevation myocardial infarction - the role of the coronary microcirculation. Swiss Med Wkly 2011;141:w13313.
3. Bekkers SC, Yazdani SK, Virmani R, et al. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 2010;55:1649-60.
4. Niccoli G, Lanza GA, Shaw S, et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J 2006;27:1793-8. (Pubitemid 44297383)
5. Niccoli G, Giubilato S, Russo E, et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J 2008;29:1843-50.
6. Jeong YH, Kim WJ, Park DW, et al. Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction. Int J Cardiol 2010;141:175-81.
7. Herring N, Cranley J, Lokale MN, et al. The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability. J Mol Cell Cardiol 2012;52:667-76.
8. Shah SH, Freedman NJ, Zhang L, et al. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet 2009;5:e1000318.
9. McDermott BJ, Bell D. NPY and cardiac diseases. Curr Top Med Chem 2007;7:1692-703. (Pubitemid 350131006)
10. Herring N, Lokale MN, Danson EJ, et al. Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway. J Mol Cell Cardiol 2008;44:477-85. (Pubitemid 351374699)
11. Clarke JG, Davies GJ, Kerwin R, et al. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet 1987;1:1057-9. (Pubitemid 17061330)
12. Gullestad L, Jorgensen B, Bjuro T, et al. Postexercise ischemia is associated with increased neuropeptide Y in patients with coronary artery disease. Circulation 2000;102:987-93. (Pubitemid 30656007)
13. Han C, Wang XA, Fiscus RR, et al. Changes in cardiac neuropeptide Y after experimental myocardial infarction in rat. Neurosci Lett 1989;104:141-6. (Pubitemid 19225603)
14. Ullman B, Hulting J, Lundberg JM. Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J 1994;15:454-61. (Pubitemid 24160692)
15. Hulting J, Sollevi A, Ullman B, et al. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 1990;24:102-8. (Pubitemid 20069483)
16. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88. (Pubitemid 26074824)
17. van't Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998;97:2302-6. (Pubitemid 28280383)
18. Ng MK, Yeung AC, Fearon WF. Invasive assessment of the coronary microcirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve. Circulation 2006;113:2054-61.
19. Hulting J, Sollevi A, Ullman B, et al. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 1990;24:102-8. (Pubitemid 20069483)
20. Omland T, Opstad K, Dickstein K. Plasma neuropeptide Y levels in the acute and early convalescent phase after myocardial infarction. Am Heart J 1994;127 (4 Pt 1):774-9.
21. Kondo K, Matsubara T, Nakamura J, et al. Characteristic patterns of circadian variation in plasma catecholamine levels, blood pressure and heart rate variability in Type 2 diabetic patients. Diabet Med 2002;19:359-65. (Pubitemid 34534209)
22. Lockinger A, Koberle D, Konig PS, et al. Neuropeptide chronomics in clinically healthy young adults: circaoctohoran and circadian patterns. Peptides 2004;25:533-42. (Pubitemid 38681051)
23. Grouzmann E, Comoy E, Bohuon C. Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors. J Clin Endocrinol Metab 1989;68:808-13. (Pubitemid 19089013)
24. Howe PR, Rogers PF, Morris MJ, et al. Plasma catecholamines and neuropeptide-Y as indices of sympathetic nerve activity in normotensive and stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 1986;8:1113-21. (Pubitemid 17211573)
25. Wocial B, Ignatowska-Switalska H, Pruszczyk P, et al. Plasma neuropeptide Y and catecholamines in women and men with essential hypertension. Blood Press 1995;4:143-7.
26. Ilhan A, Rasul S, Dimitrov A, et al. Plasma neuropeptide Y levels differ in distinct diabetic conditions. Neuropeptides 2010;44:485-9.
27. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-30. (Pubitemid 30044249)
28. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765-72. (Pubitemid 28135339)
29. Payne AR, Berry C, Doolin O, et al. Microvascular Resistance Predicts Myocardial Salvage and Infarct Characteristics in ST-Elevation Myocardial Infarction. J Am Heart Assoc 2012;1. doi:10.1161/JAHA.112.002246
30. Gullestad L, Bjuro T, Aaberge L, et al. The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris. Eur Heart J 2003;24:1120-7. (Pubitemid 36723577)